Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Exp Eye Res. 2014 May 15;124:67–73. doi: 10.1016/j.exer.2014.04.011

Figure 1. Verteporfin (VP) inhibits growth of retinoblastoma cells Y79 and WERI without light activation.

Figure 1

Y79 and WERI retinoblastoma cells were left untreated (PBS control) or treated with VP for five days; control (blue), VP concentration 2μg/ml (red) and 10μg/ml (green).

(A,B) VP treatment resulted in an inhibition of cell growth and a decrease of the cell number of Y79 and WERI cells in a dose-dependent manner. The doubling time was increased.

(C,D) VP treatment resulted in a significant, time- and dose-dependent inhibition of Y79 and WERI cell growth and viability as determined by MTT assays. The results are expressed as percentage of growth (%) relative to control values. Results are average of three independent experiments. Data are presented as mean +/− SEM (n=9, *p<0.05, *** p<0.001).